Sanofi under fire over priority US access to COVID-19 vaccine

Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More on this story

Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

14 April 2020 Sanofi and GlaxoSmithKline are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Americas

MSD buys Themis as part of COVID-19 plans

28 May 2020 Merck Sharp & Dohme is pushing forward with three initiatives aimed at combating the COVID-19 pandemic, including the acquisition of vaccine company Themis Bioscience.

Americas

Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal

3 August 2020 The US government has agreed to pay up to $2.1 billion to Sanofi and GSK for the development and delivery of 100 million doses of a COVID-19 vaccine.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent

Sanofi under fire over priority US access to COVID-19 vaccine

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features